Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuanjiao Gao

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
BMC Gastroenterology|October 1, 2018
Vanishing bile duct syndrome with hyperlipidemia after ibuprofen therapy in an adult patient: a case reportWen Xie, Qi Wang, Yuanjiao Gao, et al.
Frontiers in Cellular and Infection Microbiology|July 14, 2026
The clinical significance and optimization strategies of HBeAg seroclearance in chronic hepatitis B treatmentYaqin Zhang, Yuanjiao Gao, Xinxin Li, et al.
Biosafety and Health|July 22, 2025
Biosafety considerations triggered by genome-editing technologiesXinxin Li, Yuanjiao Gao, Ziyu Zhang, et al.
International Journal of Nanomedicine|July 6, 2026
The Application of Nanomaterials in the Detection of Liver Cancer BiomarkersDianya Qiu, Weihua Cao, Yuanjiao Gao, et al.
Journal of Viral Hepatitis|March 31, 2022
Hepatitis B core-related antigen serum levels are associated with significant liver fibrosis in treatment-naive chronic HBV infection patientsRuyu Liu, Minghui Li, Yao Lu, et al.
Frontiers in Microbiology|January 3, 2022
Advances in Metagenomics and Its Application in Environmental MicroorganismsLu Zhang, FengXin Chen, Zhan Zeng, et al.
Virulence|January 4, 2023
Nomogram for evaluating obvious liver inflammation in treatment-naïve HBeAg positive chronic hepatitis B virus infection patients with normal ALTLu Zhang, Liu Yang, Yuanjiao Gao, et al.
Biosafety and Health|November 20, 2025
Application progress and biosafety challenges of gene editing and synthetic biotechnology in diagnosis, treatment and prevention of infectious diseasesZixuan Gao, Yuanjiao Gao, Shuojie Wang, et al.
Biomed Research International|February 12, 2021
The Characteristics of Natural Killer Cells in Chronic Hepatitis B Patients Who Received PEGylated-Interferon versus Entecavir TherapyWeihua Cao, Minghui Li, Lu Zhang, et al.
Frontiers in Medicine|May 6, 2026
Analysis of risk factors and establishment of a predictive model for liver disease severity in metabolic dysfunction-associated fatty liver diseaseZiyu Zhang, Yaqin Zhang, Xinxin Li, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
BMC Gastroenterology|October 1, 2018
Vanishing bile duct syndrome with hyperlipidemia after ibuprofen therapy in an adult patient: a case reportWen Xie, Qi Wang, Yuanjiao Gao, et al.
Frontiers in Cellular and Infection Microbiology|July 14, 2026
The clinical significance and optimization strategies of HBeAg seroclearance in chronic hepatitis B treatmentYaqin Zhang, Yuanjiao Gao, Xinxin Li, et al.
Biosafety and Health|July 22, 2025
Biosafety considerations triggered by genome-editing technologiesXinxin Li, Yuanjiao Gao, Ziyu Zhang, et al.
International Journal of Nanomedicine|July 6, 2026
The Application of Nanomaterials in the Detection of Liver Cancer BiomarkersDianya Qiu, Weihua Cao, Yuanjiao Gao, et al.
Journal of Viral Hepatitis|March 31, 2022
Hepatitis B core-related antigen serum levels are associated with significant liver fibrosis in treatment-naive chronic HBV infection patientsRuyu Liu, Minghui Li, Yao Lu, et al.
Frontiers in Microbiology|January 3, 2022
Advances in Metagenomics and Its Application in Environmental MicroorganismsLu Zhang, FengXin Chen, Zhan Zeng, et al.
Virulence|January 4, 2023
Nomogram for evaluating obvious liver inflammation in treatment-naïve HBeAg positive chronic hepatitis B virus infection patients with normal ALTLu Zhang, Liu Yang, Yuanjiao Gao, et al.
Biosafety and Health|November 20, 2025
Application progress and biosafety challenges of gene editing and synthetic biotechnology in diagnosis, treatment and prevention of infectious diseasesZixuan Gao, Yuanjiao Gao, Shuojie Wang, et al.
Biomed Research International|February 12, 2021
The Characteristics of Natural Killer Cells in Chronic Hepatitis B Patients Who Received PEGylated-Interferon versus Entecavir TherapyWeihua Cao, Minghui Li, Lu Zhang, et al.
Frontiers in Medicine|May 6, 2026
Analysis of risk factors and establishment of a predictive model for liver disease severity in metabolic dysfunction-associated fatty liver diseaseZiyu Zhang, Yaqin Zhang, Xinxin Li, et al.
Pageof 3